Early kidney-replacement therapy before an absolute indication,
does it really help with Reduced 90-day mortality in severe acute kidney injury?
research showsGrade D. In the 2,927-patient STARRT-AKI analysis, 90-day death occurred in 643 (43.9%) versus 639 (43.7%), RR 1.00 (95% CI 0.93 to 1.09), P=.92. The small single-center positive ELAIN result was not reproduced by multicenter AKIKI or the much larger STARRT-AKI trial.
ads claimEarlier is not inherently better. The standard strategy still initiated therapy when hyperkalemia, acidosis, pulmonary edema, or another absolute indication emerged.
Useful facts when choosing a product
- Kidney-replacement therapy includes dialysis and hemofiltration.
- The standard arm did not withhold therapy after an absolute indication.
- Accelerated initiation increased exposure and 90-day dependence.
What the research actually shows
ELAIN was a 231-patient single-center trial. AKIKI randomized 620 across 31 French ICUs and was null for 60-day survival. STARRT-AKI randomized 3,019 across 168 sites in 15 countries and analyzed 2,927 after postrandomization exclusions. Mortality was 643/1,465 versus 639/1,462, RR 1.00. Among survivors, 90-day KRT dependence was 85/814 (10.4%) versus 49/815 (6.0%), RR 1.74 (95% CI 1.24 to 2.43). Funding came from CIHR, a CIHR-Baxter partnered grant, Australia's NHMRC, New Zealand's HRC, and the UK NIHR HTA; Alere supplied Triage MeterPro devices for NGAL measurement. Axis 6 B0 evidence ① Allocation concealment: a "centralized, computer-generated randomization schedule" was used. ② Blinding: the trial was "open-label" and the primary endpoint was all-cause death. ③ Analysis set and missing data: a "modified intention-to-treat principle" included 2,927, with exclusion reasons reported. ④ Prespecified primary endpoint: "death from any cause at 90 days" — consistent with NCT02568722.
Why this is classified as D (34)
The small positive ELAIN trial was followed by null AKIKI and 2,927-patient STARRT-AKI mortality results, giving D with 34 points.
Counterpoint. Definitions of early and delayed initiation varied, but the largest primary mortality result was exactly null.
Rejudgment record. Cross-check applied — The positive single-center ELAIN result, null multicenter AKIKI result, and large null STARRT-AKI mortality result with increased dependence were considered together
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | RX | Repeatedly refuted in the same indication |
| Independence | I1 | Mixed funding sources |
| Effect size | E0 | Null |
| Precision | C0 | The confidence interval leaves room for benefit |
The scoring table and the verdict agree (D).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced 90-day mortality | D | STARRT-AKI was exactly null. |
| Freedom from kidney-replacement therapy at 90 days | D | Dependence among survivors was higher after accelerated initiation. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| ELAIN | German single-center randomized trial | 231 | Institutional and nonprofit support | 90-day mortality | 39.3% vs 54.7%, HR 0.66, P=.03 | Small early positive trial |
| AKIKI | Randomized trial in 31 French ICUs | 619 | French Ministry of Health | 60-day survival | No difference between early and delayed strategies | Multicenter null trial |
| STARRT-AKI | Open-label randomized trial at 168 sites in 15 countries | 2,927 | CIHR, a CIHR-Baxter partnership, NHMRC, HRC New Zealand, UK NIHR HTA; Alere measurement-device support | 90-day all-cause mortality | 43.9% vs 43.7%, RR 1.00 (0.93-1.09), P=.92 | Decisive large null trial |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-08-26).
Final verification and publication gate: Codex · Verification cutoff: 2026-08-26 · Corrections: none
Cite this verdict
[Chamgap] No Benefit of Early Kidney-Replacement Therapy for 90-Day Mortality in Severe Acute Kidney Injury — Evidence Grade D·34. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/energy/early-renal-replacement-therapy-severe-aki-mortality/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.